Beperminogene perplasmid - AnGes MG

Drug Profile

Beperminogene perplasmid - AnGes MG

Alternative Names: AMG 0001 01; AMG-0001; Collategene; Hepatocyte growth factor gene therapy - AnGes MG; HGF Plasmid-AnGes-MG

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AnGes MG
  • Developer AnGes MG; Osaka University Hospital
  • Class Antiparkinsonians; Gene therapies; Ischaemic heart disorder therapies; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inducing agents; Gene transference; Hepatocyte growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Ischaemic heart disorders; Lymphoedema; Parkinson's disease

Highest Development Phases

  • Preregistration Peripheral arterial disorders
  • Phase I/II Lymphoedema
  • No development reported Arteriosclerosis obliterans; Ischaemic heart disorders; Parkinson's disease; Thromboangiitis obliterans

Most Recent Events

  • 31 Mar 2018 AnGes completes a phase II trial (alternative dosing regimen) for Peripheral arterial disorders in USA (IM) (NCT02016755)
  • 23 Jan 2018 Preregistration for Peripheral arterial disorders in Japan (IM)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Arteriosclerosis-obliterans in Japan (IM, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top